[Targeting the cyclin-dependent kinases 4/6 in advanced breast cancers].
Fiche publication
Date publication
juin 2021
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LADOIRE Sylvain
Tous les auteurs :
Coussy F, Deluche E, Pistilli B, Ladoire S, Ferrero JM, Cottu P
Lien Pubmed
Résumé
The historical median survival of advanced luminal breast cancer does not exceed four years. The deciphering of the mechanisms of resistance to hormone therapy has led to the development of inhibitors of cyclin D dependent kinases (CDK4 and 6). Three drugs, palbociclib, ribociclib and abemaciclib, very similar pharmacologically, have been evaluated in the context of pivotal, randomized phase III trials. Strikingly and regardless of the endocrine therapy backbone, and in both hormone-sensitive and hormone-resistant patients, the addition of a CDK4 / 6 inhibitor doubles progression-free survival with a hazard ratio always around 0.55. The benefit in overall survival begins to be demonstrated. This review presents all published results, as well as the main safety data.
Mots clés
Advanced breast cancer, CDK4/6 inhibitor, Cancer du sein avancé, Inhibiteur de CDK4/6
Référence
Bull Cancer. 2021 Jun 18;: